Sanofi MS Drug's Mixed Verdict at FDA Panel Puzzles Analysts

Sanofi MS Drug's Mixed Verdict at FDA Panel Puzzles Analysts

The FDA is expected to decide whether to approve Lemtrada by Dec. 27. The agency will probably issue a so-called complete response letter that rejects the drug until the company does further work, said Jeffrey Holford, an analyst at Jefferies in New York.

2
Like
Save

Comments

Write a comment

*